European Consumers Embrace Elixinol Hemp Oil CBD as Part of Wellness Movement
Elixinol Brand Cannabidiol Hemp Oil Now Available Throughout Europe
DENVER, July 19, 2017 (GLOBE NEWSWIRE) -- Already regarded as one of the fastest growing and most trusted cannabidiol brands in the world, Elixinol announces expansion into Europe.
Photos accompanying this announcement are available at:
Seven Elixinol hemp oil CBD products will be available to consumers throughout Europe including best-sellers such as Liposomes, noted for their great taste and increased bioavailability, the targeted topical Rescue Balm, and CBD capsules.
Consumers throughout the world use Elixinol's CBD hemp oil for both lifestyle improvement and condition treatment. Elixinol expects Europeans will embrace CBD hemp oil products as part of an overall wellness regimen.
"Faced with shrinking healthcare budgets and an increased emphasis on well-being, European consumers are looking for ways to get better rest, reduce stress and optimize their fitness efforts," said Husong.
With increasing numbers of consumers in Europe embracing fitness, organic foods and stress reduction, Elixinol's market entry meets the needs of the growing marketplace.
According to Statista, over 52% of Western Europeans rated their own health knowledge as sufficient or excellent, "translating into greater understanding of health measures and what individuals should do to improve their own health." The health and wellness market value in Western Europe is already over 145 million euros with more growth projected. Western Europe's dietary supplement market is projected to reach over 5.6 million euros by 2020.
"From executives who crave increased focus and stress reduction to fitness aficionados seeking faster recovery, since we launched, sales in Europe have exceeded our aggressive expectations," said Chris Husong, Director of Global Marketing and Sales for Elixinol.
"Hemp and its benefits are nothing new for Europeans," said Marco Cappiello, Director of European Operations for Elixinol. "But with concerns over serving size, potency and purity now addressed by Elixinol's rigorous and transparent testing process, Europeans can now purchase CBD hemp oil with confidence," he continued.
To eliminate consumer concerns about metals, solvents, pesticides as well as potency and purity, Elixinol is the only global brand to post independent laboratory test results online and follows a strict pharmaceutical-grade testing process.
Elixinol will source its European CBD from existing relationships with Northern European organic farmers who have been cultivating hemp for generations.
"It's as if we're coming home," said Husong. "We've had relationships in Europe since our inception, being able to deliver the end product to the European consumer is incredibly satisfying."
Elixinol products are available to customers in Europe on elixinol.com and in various retail health outlets throughout Spain and Italy.
Colorado-based Elixinol, founded by Paul Benhaim, hemp entrepreneur since 1991, is widely regarded as one of the most influential CBD brands in the world. With a proven track record of growing and manufacturing high-quality hemp, Elixinol also conducts rigorous laboratory testing and quality control. A global leader in hemp distribution, Elixinol distributes CBD products in 22 countries globally including United States, Japan, Puerto Rico, Brazil and throughout Europe. More information available at Elixinol.com.
Photos may also be available via AP PhotoExpress.
+1 844-804-3504 ext 420
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Elixinol via Globenewswire
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
BDA partners with government to attract cryptocurrency23.11.2017 06:25 | Pressemelding
HAMILTON, Bermuda, Nov. 23, 2017 (GLOBE NEWSWIRE) -- The Bermuda Business Development Agency (BDA) will take a lead role in an initiative launched by the Bermuda government today to accelerate the establishment and growth of digital currency business on the island. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/457f43b9-d7bb-48f1-83e2-b856b33ebacc At a press conference held by Premier the Hon David Burt and National Security Minister the Hon Wayne Caines, the government announced the formation of a task force comprising two teams to advance Bermuda's regulatory environment as a destination for utility tokens, tokenised securities, cryptocurrencies, and coin offerings. BDA Consultant for Emerging Technologies John Narraway was named as chair of the Blockchain Business Development Working Group, while BDA Board member Lydia Dickens will chair the Blockchain Legal and Regulatory Working Group, of which
VistaJet Partners With Christie's for the Global Tour of The Collection of Peggy and David Rockefeller22.11.2017 11:39 | Pressemelding
The sale will be the most significant philanthropic auction ever presented LONDON, Nov. 22, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global private aviation company, announces today its worldwide sponsorship of the exhibition and tour of The Collection of Peggy and David Rockefeller, the most significant auction entirely dedicated to raising funds for philanthropic causes. The sale, consisting of numerous categories, will be conducted by Christie's, the world's leading art business, and will include a highlights exhibition tour in Hong Kong, London, Los Angeles and New York. Photos accompanying this announcement are available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c78fdce7-7651-42a8-a621-14088da2cc86 http://www.globenewswire.com/NewsRoom/AttachmentNg/33af2489-a9a8-4bbe-b5f7-78e4c1f29ca2 http://www.globenewswire.com/NewsRoom/AttachmentNg/a16c2
Nasdaq to Deliver Blockchain e-Voting Solution to Strate22.11.2017 10:00 | Pressemelding
South Africa's central securities depository (CSD) will leverage the solution to improve voting efficiencies and increase shareholder participation in South Africa STOCKHOLM, Sweden and JOHANNESBURG, South Africa, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) and Strate (Pty) Ltd, the South African CSD, announced today an agreement for Nasdaq to deliver a new blockchain solution that would bring electronic voting to the South African capital markets. The solution will allow Strate, in conjunction with key stakeholders in the market, to provide general meeting services and give shareholders an easy, user-friendly and secure tool for voting remotely. The solution is based on the successful proof of concept (PoC) developed for Nasdaq's Estonia market. In addition, Strate will contribute to the ongoing market development of e-Voting technology. "We are very excited about our initiative with Nasdaq and what it means for the South African financial markets," said Tan
Oxford Immunotec to Present at the 29th Annual Piper Jaffray Healthcare Conference21.11.2017 15:15 | Pressemelding
OXFORD, United Kingdom and MARLBOROUGH, Mass., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Peter Wrighton-Smith, Chief Executive Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28th, at 12:00 p.m. EST. The conference will be held at the Lotte New York Palace. A live webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.oxfordimmunotec.com. A webcast replay will be available approximately two hours after the live presentation and will be archived on the website for approximately 90 days. About Oxford Immunotec Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and comme
CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs21.11.2017 14:00 | Pressemelding
SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint publications illustrate the utility of Crown Bioscience's proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies. The research conducted by Crown Bioscience, Eli Lilly and Company and Ball State University was published in two PLOS ONE papers: Peterson et al. Glucose dysregulation and response to common anti-diabetic agents in the FATZO/Pco model PLOS One 2017;12 (6):e0179856, https://doi.org/10.1371/journal.pone.0179856 Droz et al. Correlation of disease severity with body weight and high fat diet in the FATZO/Pco model PLOS One 2017;1
OmniComm Systems Signs Letter of Intent to Acquire Certain Assets of Algorithm and its Subsidiary Algorics21.11.2017 14:00 | Pressemelding
Acquisition Will Expand OmniComm's Product Line With Data Analytics and Risk-Based Monitoring Solutions FORT LAUDERDALE, Fla., Nov. 21, 2017 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX:OMCM), a leading global provider of clinical data management technology, and Algorithm, Inc. and its subsidiaries Algorics Ltd. and Algorithm Informatics Pvt. Ltd. (collectively, "Algorics"), have signed a letter of intent ("LOI"), under which OmniComm will acquire certain assets and assume certain liabilities of Algorics, a provider of clinical analytics solutions and software. By combining forces, the companies expect increased operating efficiency, strengthened traction in the maturing risk-based approach solution area, new marketing opportunities and an expanded portfolio of electronic data capture (EDC) solutions for the global clinical trials industry. The transaction would also provide OmniComm with an office in India, a country of growing importance in t
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom